11119 North Torrey Pines Road
136 articles with Viking Therapeutics
Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.5 million.
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
Viking Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Top-Line Results Expected in Second Half of 2018
Viking Therapeutics, Inc. announced that the company will release financial results for the first quarter of 2018 after the market close on Wednesday, May 9, 2018.
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
Viking Therapeutics Inc. announced its financial results for the fourth quarter and year ended December 31, 2017, and provided an update on its clinical pipeline and other corporate developments.
The gross proceeds to Viking from this offering are approximately $63.3M, before deducting underwriting discounts and commissions and other estimated offering expenses.
In addition, Viking has granted the underwriters a 30-day option to purchase up to 1,650,000 additional shares of its common stock.
Viking today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
12/20/2017When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.
The gross proceeds to Viking from this offering are approximately $14.8M, before deducting underwriting discounts and commissions and other estimated offering expenses.
Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $12.8M.
All of the shares to be sold in the offering are to be sold by Viking.
Viking Therapeutics Announces Positive Top-Line Results From Phase II Study of VK5211 in Patients Recovering From Hip Fracture
Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, following treatment with VK5211 as compared to placebo.
Research and development expenses for the three months ended September 30, 2017 were $3.5 million compared to $2.1 million for the same period in 2016.
Brian Lian, Ph.D., Viking's president and CEO, and Michael Morneau, Viking's CFO, will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, November 8, 2017.
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed NASH at the Annual Meeting of the AASLD
Viking today announced positive final results from an eight-week study of VK2809 in an in vivo model of NASH.
Viking Therapeutics Presents Results From Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
Viking today announced positive results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics Announces Top-Line Results From Proof-Of-Concept Study Of VK0214 In In Vivo Model Of X-Linked Adrenoleukodystrophy (X-Ald)
Viking Therapeutics Announces Purchase Agreements For Up To $16.25 Million With Lincoln Park Capital